Posts

UK launches national dementia registry to speed up search for treatments

The UK has launched a national dementia registry called BARBARA (Brain Ageing Registry for Biomarkers, Access to Trials, Research and Adoption) to speed up the search for treatments. BARBARA links 180 existing dementia research databases and population health studies to efficiently identify suitable clinical trial participants. The registry is funded jointly by the UK government, charities, and the pharmaceutical industry, aiming to boost life sciences investment and improve R&D competitiveness. The platform is designed to help drug companies quickly recruit participants and give people with dementia or at risk better access to appropriate studies. BARBARA also supports early detection through emerging blood biomarkers, enabling enrollment before clear clinical symptoms appear. The total investment for the platform is expected to be announced later this year. Sources: UK links 180 dementia databases to speed drug trials and lure R&D ... UK dementia diagnoses ris...

Recent News About Tris Pharma's Narcolepsy Drug and Agenus' Phase 3 CRC Trial Abandonment

Innovent deal seeds Spero’s future beyond GSK’s antibiotic, opening an oncology pipeline in 2026

US Physicians Cautious About AI‑Driven Home Testing

Tenpoint Therapeutics Submits MAA for YUVEZZI to MHRA for Presbyopia Treatment in Adults

Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform

FDA Releases 14 New Drug Rejection Letters After 3‑Month Pause in Transparency Policy

GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win

Germany pushes through healthcare reform package despite pharma's drug discount resistance

AAIC 2026: Tau-targeted Alzheimer treatments heat up while amyloid therapies persist

U.S. Biotechs Go Dark as China's Biotech Rise Sparks Paranoia

Hansoh Hits Phase III SCLC Goal

FDA Rejects Hengrui-Elevar Liver Cancer Drug Combo for Third Time due to Manufacturing Concerns